CD20阳性儿童B系急性淋巴细胞白血病临床特点及生存分析  

Clinical features and survival analysis of children with CD20 positive B-precursor acute lymphoblastic leukemia

作　　者：袁媛[1] 欧丹艳[1] 何云燕[1] 罗建明[1] 唐咸艳 

机构地区：[1]广西医科大学第一附属医院儿科,南宁530021

出　　处：《中国小儿血液与肿瘤杂志》2013年第5期222-225,共4页Journal of China Pediatric Blood and Cancer

基　　金：广西卫生厅青年基金项目(No.Z2011343)

摘　　要：目的探讨儿童B系急性淋巴细胞白血病(B precursor acute lymphoblastic leukemia,B-ALL)CD20抗原表达情况与临床特点及预后的关系。方法回顾性分析广西医科大学第一附属医院儿科血液病房2005年1月-2012年8月收治的200例初诊B-ALL患儿临床特点和生存情况。结果 CD20阳性54例(27%),阴性146例(73%),两组患儿在性别、年龄、外周血白细胞计数、血红蛋白水平、血小板计数、骨髓幼稚细胞数、FAB分型、细胞遗传学改变、初诊时中枢神经系统白血病发生、临床危险度分型及诱导缓解治疗第19 d骨髓状态的差异无显著性;Kaplan-Meier曲线生存率分析显示,CD20阳性和CD20阴性组B-ALL患儿的预计3年EFS分别为(65.5±10.1)%和(70.3±5.7)%,两组差异无显著性(P=0.677)。结论 CD20在儿童B-ALL中的表达与一般临床特点及预后无关,尚不能作为B-ALL危险度的预测因素。Objective To explore the clinical features and survival rates of children with CD20 positive B-precursor acute lymphoblastic leukemia （B-ALL）.Methods The clinical manifestations,laboratory examinations,therapeutic effect and survival rates of 200 B-ALL patients treated in our hospital from January 2005 to August 2012 were analyzed retrospectively.Results：A total of 200 cases including 54 CD20＋ B-ALL cases （27%） and 146 CD20-B-ALL cases （73%） were enrolled in this study.There was no difference between two groups among gender,age,the peripheral white blood cell counts,hemoglobin,platelet counts,the bone marrow （BM） blast cell counts,FAB classification,cytogenetic abnormalities,central nervous system involvement at diagnosis,clinical risk classification and BM status at the 19th day of induction chemotherapy.The analysis of Kaplan-Meier curve on survival rate demonstrated that the 3-year EFS of patients in CD20 ＋ and CD20-groups were （65.5 ± 10.1） % and （70.3 ± 5.7） %,respectively,and no statistical difference was found （P =0.677）.Conclusions CD20 expression has no relationship with the clinical features and prognosis of children with B-ALL.CD20 could not be considered as an independent predictor of risk factors in pediatric B-ALL.

关 键 词：白血病 淋巴细胞性 急性 CD20 临床特点 生存分析 

分 类 号：R733.7[医药卫生—肿瘤]